Evidence map›Paper›PMID 34344959›Full record

ArticleScientific reports2021

Induction of interferon response by high viral loads at early stage infection may protect against severe outcomes in COVID-19 patients.

Eric C Rouchka, Julia H Chariker, Brian Alejandro, Robert S Adcock, Richa Singhal, Julio Ramirez, Kenneth E Palmer, Amanda B Lasnik, Ruth Carrico, Forest W Arnold and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Letter to the editor: Viral load decline time offers theoretical insight rather than practical value.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Interleukin (IL)-33 immunobiology in asthma and airway inflammatory diseases.The Journal of asthma : official journal of the Association for the Care of Asthma · 2022
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Eric C RouchkaDepartment of Computer Science and Engineering, University of Louisville, Louisville, KY, USA.
Julia H CharikerKentucky IDeA Network of Biomedical Research Excellence (KY-INBRE) Bioinformatics Core, Louisville, KY, USA.
Brian AlejandroDepartment of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville, KY, USA.
Robert S AdcockCenter for Predictive Medicine, University of Louisville School of Medicine, Louisville, KY, USA.
Richa SinghalKentucky IDeA Network of Biomedical Research Excellence (KY-INBRE) Bioinformatics Core, Louisville, KY, USA.
Julio RamirezDepartment of Medicine, University of Louisville, Louisville, KY, USA.
Kenneth E PalmerCenter for Predictive Medicine, University of Louisville School of Medicine, Louisville, KY, USA.
Amanda B LasnikCenter for Predictive Medicine, University of Louisville School of Medicine, Louisville, KY, USA.
Ruth CarricoDepartment of Medicine, University of Louisville, Louisville, KY, USA.
Forest W ArnoldDepartment of Medicine, University of Louisville, Louisville, KY, USA.
Stephen FurmanekDepartment of Medicine, University of Louisville, Louisville, KY, USA.
Mei ZhangDepartment of Medicine, University of Louisville, Louisville, KY, USA.
Leslie A WolfDivision of Infectious Diseases, University of Louisville, Louisville, KY, USA.
Sabine WaigelDepartment of Medicine, University of Louisville, Louisville, KY, USA.
Wolfgang ZachariasDepartment of Medicine, University of Louisville, Louisville, KY, USA.
Jose BordonWashington Health Institute, George Washington University School of Medicine, Washington, D.C, USA.
Donghoon ChungDepartment of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville, KY, USA. hoon.chung@louisville.edu.ORCID 0000-0003-2626-172X
University of Louisville · USGeorge Washington University · US

Funding

WKU Lead Faculty AwardP20GM103436 · NIGMS · UNIVERSITY OF LOUISVILLE · PI ERIC C ROUCHKA · 2012 to 2026
$60.1M
NIGMS NIH HHS P20 GM103436
6 · The paper itself

Abstract

Key elements for viral pathogenesis include viral strains, viral load, co-infection, and host responses. Several studies analyzing these factors in the function of disease severity of have been published; however, no studies have shown how all of these factors interplay within a defined cohort. To address this important question, we sought to understand how these four key components interplay in a cohort of COVID-19 patients. We determined the viral loads and gene expression using high throughput sequencing and various virological methods. We found that viral loads in the upper respiratory tract in COVID-19 patients at an early phase of infection vary widely. While the majority of nasopharyngeal (NP) samples have a viral load lower than the limit of detection of infectious viruses, there are samples with an extraordinary amount of SARS-CoV-2 RNA and a high viral titer. No specific viral factors were identified that are associated with high viral loads. Host gene expression analysis showed that viral loads were strongly correlated with cellular antiviral responses. Interestingly, however, COVID-19 patients who experience mild symptoms have a higher viral load than those with severe complications, indicating that naso-pharyngeal viral load may not be a key factor of the clinical outcomes of COVID-19. The metagenomics analysis revealed that the microflora in the upper respiratory tract of COVID-19 patients with high viral loads were dominated by SARS-CoV-2, with a high degree of dysbiosis. Finally, we found a strong inverse correlation between upregulation of interferon responses and disease severity. Overall our study suggests that a high viral load in the upper respiratory tract may not be a critical factor for severe symptoms; rather, dampened antiviral responses may be a critical factor for a severe outcome from the infection.

Indexed as

AdultAgedCOVID-19DysbiosisFemaleHumansInterferonsMaleMetagenomicsMicrobiotaMiddle AgedNasopharynxReal-Time Polymerase Chain ReactionRespiratory SystemRNA, ViralSARS-CoV-2InterferonsRNA, Viral

Identifiers

PMID34344959
PMCPMC8333042
OpenAlexW3190981607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.